OncoMatch/Clinical Trials/NCT05773859
NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer
Is NCT05773859 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies XP-DC vaccinations for epithelial ovarian cancer.
Treatment: XP-DC vaccinations — This goal of this single arm, single center, exploratory phase I/II clinical trial is to learn more about the immunological efficacy, safety and feasibility of an autologous tumor lysate-loaded autologous XP-DC (cDC1)-based vaccine in patients with ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Disease stage
Required: Stage FIGO IIIB, FIGO IIIC, FIGO IVA, FIGO IVB IF ONLY LYMPH NODES ≤ 1CM ABOVE THE DIAPHRAGM OR IN THE GROINS (FIGO)
Excluded: Stage FIGO I, FIGO IIB, FIGO IIIA, FIGO IVB WITH LIVER, SPLEEN OR LUNG METASTASES OR LYMPH NODES ABOVE THE DIAPHRAGM OR IN THE GROINS > 1 CM
Grade: high-gradelow grade
FIGO stage IIIb, IIIc, IVa or IVb if only lymph nodes ≤ 1cm above the diaphragm or in the groins; FIGO stage I-IIb, IIIa or IVb with liver, spleen or lung metastases or lymph nodes above the diaphragm or in the groins > 1 cm [excluded]
Performance status
WHO/ECOG 0–1
Prior therapy
Lab requirements
Blood counts
Neutrophils >1.5x 10^9/L, platelets >100x 10^9/L, hemoglobin >5.6 mmol/L (9.0 g/dl)
Kidney function
estimated glomerular filtration rate > 45 ml/min/1.73m2
Liver function
AST/ALT <3 x ULN, serum bilirubin <1.5 x ULN (exception: Gilbert's syndrome is permitted)
Neutrophils >1.5x 10^9/L, platelets >100x 10^9/L, hemoglobin >5,6 mmol/L (9.0 g/dl), estimated glomerular filtration rate > 45 ml/min/1.73m2 , AST/ALT <3 x ULN, serum bilirubin <1.5 x ULN (exception: Gilbert's syndrome is permitted)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify